Lupin Ltd., a top
pharma company, rose for the second day in a flat to weak market on news that the company had got a nod from the US pharma regulator to sell an anti-inflammatory drug.
Lupin said it got an approval from the
US FDA to sell its version of Diclofenac Sodium in the US market, which helped its shares to buck a wider trend.
Lupin rose 45 rupees, or 2.5 percent, to 1,873 rupees on the
National Stock Exchange, where 9.03 lakh shares were traded compared with the 5-day average of 17.8 lakh shares.
Lupin's market capitalisation has gained 46 percent in the past one year to 82,900 crore rupees as investors preferred the relative safety of export-oriented pharma companies.
Image credit: Indiatimes
